VA
VR Adviser Portfolio holdings
AUM
$1.33B
1-Year Return
6.92%
This Quarter Return
+19.93%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.33B
AUM Growth
+$159M
(+14%)
Cap. Flow
+$21.6M
Cap. Flow
% of AUM
1.62%
Top 10 Holdings %
Top 10 Hldgs %
74.55%
Holding
40
New
3
Increased
5
Reduced
6
Closed
9
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$34.7M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$32.2M |
| 3 |
CytomX Therapeutics
CTMX
|
$31.7M |
| 4 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$21.9M |
| 5 |
Savara
SVRA
|
$12.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$37.5M |
| 2 |
Cidara Therapeutics
CDTX
|
$20.1M |
| 3 |
Pharvaris
PHVS
|
$18.7M |
| 4 |
Dianthus Therapeutics
DNTH
|
$13.9M |
| 5 |
Solid Biosciences
SLDB
|
$9.18M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.26B
| $369M | 27.64% |
8,493,321
| – | – |
|
2
Ocular Therapeutix
OCUL
$2.37B
| $118M | 8.88% |
12,762,462
| – | – |
|
|
MTSR
3
Metsera, Inc. Common Stock
MTSR
$3.77B
| $107M | 8% |
3,750,662
| – | – |
|
4
Enliven Therapeutics
ELVN
$1.19B
| $80.8M | 6.05% |
4,026,331
| – | – |
|
5
KalVista Pharmaceuticals
KALV
$796M
| $76.1M | 5.7% |
6,728,985
+25,000
| +0.4% | +$283K |
|
|
6
Oric Pharmaceuticals
ORIC
$1.06B
| $67M | 5.02% |
6,596,885
+3,414,358
| +107% | +$34.7M |
|
7
Viridian Therapeutics
VRDN
$1.53B
| $54.3M | 4.07% |
3,882,709
| – | – |
|
|
ORKA
8
Oruka Therapeutics, Inc. Common Stock
ORKA
$612M
| $46.5M | 3.48% |
4,148,428
| – | – |
|
9
Spyre Therapeutics
SYRE
$1.03B
| $40.2M | 3.01% |
2,685,448
| – | – |
|
|
10
Pharvaris
PHVS
$1.48B
| $36M | 2.7% |
2,047,620
-1,065,100
| -34% | -$18.7M |
|
11
Cogent Biosciences
COGT
$1.82B
| $34.1M | 2.56% |
4,755,411
-929,000
| -16% | -$6.67M |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $32.2M | 2.41% |
+3,220,364
| New | +$32.2M |
|
|
13
CytomX Therapeutics
CTMX
$376M
| $31.7M | 2.38% |
+13,969,882
| New | +$31.7M |
|
|
14
Cidara Therapeutics
CDTX
$1.6B
| $31.1M | 2.33% |
639,088
-412,430
| -39% | -$20.1M |
|
|
UPB
15
Upstream Bio, Inc. Common Stock
UPB
$1.08B
| $25.2M | 1.89% |
2,295,319
| – | – |
|
16
Erasca
ERAS
$457M
| $22.7M | 1.7% |
17,857,083
+1,640,867
| +10% | +$2.08M |
|
|
CBIO
17
Crescent Biopharma, Inc. Common Stock
CBIO
$198M
| $22.4M | 1.68% |
1,387,864
+1,357,864
| +4,526% | +$21.9M |
|
18
Dyne Therapeutics
DYN
$2.02B
| $20.7M | 1.55% |
2,173,913
| – | – |
|
|
19
Savara
SVRA
$643M
| $20.3M | 1.52% |
8,884,263
+5,626,624
| +173% | +$12.8M |
|
|
20
Dianthus Therapeutics
DNTH
$853M
| $18.6M | 1.4% |
1,000,000
-744,373
| -43% | -$13.9M |
|
21
enGene Holdings
ENGN
$265M
| $18.4M | 1.38% |
5,046,414
| – | – |
|
22
Astria Therapeutics
ATXS
$424M
| $13.2M | 0.99% |
2,457,348
| – | – |
|
23
Cullinan Oncology
CGEM
$413M
| $10.4M | 0.78% |
1,379,965
| – | – |
|
|
ABVX
24
Abivax
ABVX
$6.65B
| $10.3M | 0.77% |
1,345,780
| – | – |
|
|
PCSC
25
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
| $7.97M | 0.6% |
750,000
| – | – |
|